S L Haskell

Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution

Agnès Girard, D Girard, A. R. English et al. · Antimicrobial Agents and Chemotherapy · 1987 · 323 citations

Medicine, Pharmacokinetics, Pharmacology +14

Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro

Thomas D. Gootz, Richard P. Zaniewski, S L Haskell et al. · Antimicrobial Agents and Chemotherapy · 1996 · 137 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Bisulfite or sulfite inhibits growth of Helicobacter pylori

Steven J. Hawrylik, David J. Wasilko, S L Haskell et al. · Journal of Clinical Microbiology · 1994 · 45 citations · Full text

Life Sciences, Microbiology, Bacteriology +8

In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial

Thomas D. Gootz, Katherine E. Brighty, Marge R. Anderson et al. · Diagnostic Microbiology and Infectious Disease · 1994 · 41 citations

Pharmacy, Medicinal Chemistry, Pharmacology +8

Structure-activity relationships of 6-(heterocyclyl)-methylene penam sulfones. A new class of .BETA.-lactamase inhibitors.

Yuhpyng L. Chen, Cnm-Wu CHANG, K. HEDBERG et al. · The Journal of Antibiotics · 1987 · 38 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16